Analyst Roundtable: Medicare Part D, Pipeline Innovation and the Challenges Ahead
You may also be interested in...
FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response
Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.